2016
DOI: 10.1111/bph.13634
|View full text |Cite
|
Sign up to set email alerts
|

Functional pharmacological characterization of SER100 in cardiovascular health and disease

Abstract: SER100 exerts a chronic hypotensive and bradycardic effects in rodents, including models of systemic and pulmonary hypertension. SER100 produces its cardiovascular effects, at least in part, by inhibition of cardiac and vascular sympathetic activity. SER100 may represent a novel therapeutic candidate in systemic and pulmonary hypertension.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 63 publications
(87 reference statements)
0
7
0
Order By: Relevance
“…Cut-off frequencies previously determined to be accurate for mice were used to divide the signal into three components: very low frequency (Ͻ0.4 Hz), low frequency (LF 0.4 -1.5 Hz), and high frequency (HF 1.5-4.0 Hz). Normalization to exclude very low frequency was performed, and the spectral variability at each bandwidth was normalized to the total spectral area (69).…”
Section: Methodsmentioning
confidence: 99%
“…Cut-off frequencies previously determined to be accurate for mice were used to divide the signal into three components: very low frequency (Ͻ0.4 Hz), low frequency (LF 0.4 -1.5 Hz), and high frequency (HF 1.5-4.0 Hz). Normalization to exclude very low frequency was performed, and the spectral variability at each bandwidth was normalized to the total spectral area (69).…”
Section: Methodsmentioning
confidence: 99%
“…Via selective activation of the NOP receptor, N/OFQ modulates several biological functions including pain transmission, learning and memory, emotional states, locomotor activity, food intake, drug abuse, cardiovascular and gastrointestinal functions, and the cough and micturition reflexes [40]. N/OFQ and synthetic NOP receptor agonists have been shown to produce beneficial effects in different animal models of Formatted: Font: Italic pathology [41] and, currently, some of these molecules are in clinical development including cebranopadol [42] as innovative analgesic [43], SER100 (alias ZP-120 [18]) for systolic hypertension [44] [45] and REC 0438 (alias UFP-112, [46]) for urinary incontinence due to overactive bladder [47].…”
Section: Pwt-n/ofqmentioning
confidence: 99%
“…Reversed-phase column chromatography (2:3, MeCN:H 2 O) afford the title compound as a white solid (0.040 g, 0.100 mmol, 26%). (36). To a solution of 30 (100 mg, 0.379 mmol) and t-Bu glycine HCl (95 mg, 0.569 mmol) in dry DMF (2 mL) at r.t. was added triethylamine (0.133 mL, 0.95 mmol), and the mixture was stirred at 80 °C for 3 h (TLC, LCMS).…”
Section: ■ Experimental Sectionmentioning
confidence: 99%